Free Trial

Exscientia Q4 2023 Earnings Report

Exscientia logo
$4.84 +0.15 (+3.20%)
(As of 11/20/2024)

Exscientia EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Exscientia Revenue Results

Actual Revenue
$3.10 million
Expected Revenue
$41.63 million
Beat/Miss
Missed by -$38.53 million
YoY Revenue Growth
N/A

Exscientia Announcement Details

Quarter
Q4 2023
Time
N/A
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Exscientia Earnings Headlines

Exscientia and Recursion Merge to Revolutionize Drug Discovery
Recursion, Exscientia officially combine to advance drug discovery
Fed Declares War on Americans
Fed Declares War on Americans Protect your wealth in the coming months…
Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)
Recursion and Exscientia Merger Approved by Shareholders
See More Exscientia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exscientia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exscientia and other key companies, straight to your email.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

View Exscientia Profile

More Earnings Resources from MarketBeat